Pfizer Inc. $PFE Shares Purchased by Jain Global LLC

Jain Global LLC raised its position in Pfizer Inc. (NYSE:PFE) by 32.3% during the third quarter, Holdings Channel reports. The firm owned 402,600 shares of the biopharmaceutical company’s stock after buying an additional 98,303 shares during the quarter. Jain Global LLC’s holdings in Pfizer were worth $10,258,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of PFE. Brighton Jones LLC lifted its stake in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC grew its position in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares in the last quarter. United Bank increased its stake in Pfizer by 12.4% during the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after purchasing an additional 6,415 shares during the period. Foundations Investment Advisors LLC increased its stake in Pfizer by 1.4% during the second quarter. Foundations Investment Advisors LLC now owns 76,044 shares of the biopharmaceutical company’s stock worth $1,843,000 after purchasing an additional 1,081 shares during the period. Finally, Avantax Advisory Services Inc. lifted its position in shares of Pfizer by 14.6% during the second quarter. Avantax Advisory Services Inc. now owns 423,497 shares of the biopharmaceutical company’s stock worth $10,266,000 after purchasing an additional 54,086 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the subject of several recent research reports. Wolfe Research set a $24.00 price objective on shares of Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. BMO Capital Markets reaffirmed an “outperform” rating and set a $30.00 target price on shares of Pfizer in a research note on Monday, March 9th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. Daiwa Securities Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target for the company. in a research note on Thursday, February 12th. Finally, Barclays began coverage on Pfizer in a research report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $28.05.

Pfizer Stock Up 0.1%

Shares of NYSE:PFE opened at $26.61 on Tuesday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94. The firm’s 50 day moving average price is $26.53 and its 200 day moving average price is $25.54. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The stock has a market cap of $151.28 billion, a price-to-earnings ratio of 19.56 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. During the same quarter in the previous year, the business posted $0.63 EPS. The firm’s revenue was down 1.2% on a year-over-year basis. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.